Lasmiditan is being developed for the acute treatment of migraine with and without aura in adults. Lasmiditan and other compounds in its class lack vasoconstrictor activity in vitro and lasmiditan has not been associated with significant adverse cardiovascular effects in five completed clinical studies (two i.v. and three oral administration studies).
Its central neural mechanism of action and lack of vasoconstrictor activity may make lasmiditan suitable for use as a first line therapy in acute migraine sufferers, to include those patients with risk factors for cardiovascular disease as well as patients dissatisfied with triptans and ergot derivatives.
Phase 3 development will include:
- Confirmatory efficacy studies in patients with acute migraine
- Efficacy studies in patients with repeated attacks
- Clinical pharmacology studies to further characterize pharmacologic properties of lasmiditan
- Significant safety experience database in migraine sufferers
